Eisai Co., Ltd. has refiled for the approval of an ultra-high dose of mecobalamin (E0302) for the treatment of amyotrophic lateral sclerosis (ALS) in Japan, following its withdrawal of a previous application several years ago due to insufficient clinical data.
If approved, the country would be the first globally clear the injected drug for ALS, for which several other oral...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?